Page 5 - Structural Protein News Today

GSK-3 inhibitors show promise in treating coronavirus infections Researchers in the United States have suggested a new approach to treating infection with coronaviruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19). The study showed that inhibiting phosphorylation of a key structural protein expressed on coronaviruses impaired SARS-CoV-2 infection in human lung epithelial cells. The team used inhibitors of the ...

Researchers in the United States have successfully delivered a critical structural protein found in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to a human cell line and tracked its localization deep within the cells.

Could rotavirus vaccine platforms aid in the immunization campaign against SARS-CoV-2? Rotavirus is a common diarrheal disease that affects young children. Live oral rotavirus vaccines have been used to reduce its incidence in many countries. However, with the onset of the coronavirus disease 2019 (COVID-19) pandemic, and amid focus on vaccines as the only definitive method of durable control, a new study describes the possibility of producing a combined vaccine against both infections. The stu...

The current pandemic of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is still spreading rapidly throughout the world. A new preprint on the bioRxiv* server describes the structure of an important viral non-structural protein NSP12-16 and its role in SARS-CoV-2 infection.

In a recent medRxiv research paper, the US scientists examined the effects of non-synonymous mutations in the circulating B.1.1.7 strain of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on linear antibody epitope signal for viral spike glycoprotein and nucleoprotein – and demonstrated that mutations should not result in immune evasion.